|Application ||IF, Func|
|Clone Names||2D12 (0G5)|
|Immunogen||17D strain of yellow fever virus|
|Shelf Life||12 months from date of reconstitution.|
|Target/Specificity||Mouse anti-Yellow fever virus antibody, clone 2D12 recognizes the envelope protein of the wild (Asibi) and vaccine strains of yellow fever virus. The clone has been reported to have neutralising activity against the Asibi strain (Schlessinger et al. 1984). No cross reactivity with other flaviviruses has been reported.|
|Preservative & Stabilisers||Preservative Free|
|Storage||Store at -20℃ only.|
|Precautions||Anti-Yellow Fever Virus Antibody, clone 2D12 (0G5) (Ascites) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Schlesinger, J.J. et al. (1983) Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein.Virology. 125 (1): 8-17. 2. Schlesinger, J.J. & Brandriss, M.W. (1983) 17D yellow fever virus infection of P388D1 cells mediated by monoclonal antibodies: properties of the macrophage Fc receptor.J Gen Virol. 64 (Pt 6): 1255-62. 3. Schlesinger, J.J. et al. (1984) Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies.J Gen Virol. 65 ( Pt 10): 1637-44. 4. Gandini, M. et al. (2011) Dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF-α and IFN-α profiles.Mem Inst Oswaldo Cruz. 106 (5): 594-605. 5. Monath, T.P. et al. (1986) Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens.J Clin Microbiol. 23 (1): 129-34. 6. Brandriss, M.W. et al. (1986) Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.J Gen Virol. 67 ( Pt 2): 229-34. 7. Op De Beeck, A. et al. (2003) Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope.J Virol. 77 (2): 813-20. 8. Izurieta, R.O. et al. (2009) Anamnestic immune response to dengue and decreased severity of yellow Fever.J Glob Infect Dis. 1 (2): 111-6. 9. Thonnon, J. et al. (1998) Re-emergence of yellow fever in Senegal in 1995.Am J Trop Med Hyg. 59 (1): 108-14. 10. Thonnon, J.et al. (1998) Yellow fever outbreak in Kaffrine, Senegal 1996: epidemiological and entomological findings.Trop Med Int Health. 3 (11): 872-7. 11. Op De Beeck, A. et al. (2004) The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals.J Virol. 78 (22): 12591-602. 12. Ciczora, Y. et al. (2010) Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein.J Gen Virol. 91 (Pt 2): 404-14. 13. Vratskikh, O. et al. (2013) Dissection of antibody specificities induced by yellow fever vaccination.PLoS Pathog. 9 (6): e1003458.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.